Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy ...
Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returning after surgery ...
Super Early Bird pricing EXTENDED! Save 40% right now to join your peers for learning, laughter, and lobster rolls at B2B Forum. Grow your marketing and leadership skills, meet new friends, and get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results